Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Operating Leases (2019 - 2026)

Summit Therapeutics filings provide 8 years of Operating Leases readings, the most recent being $16.9 million for Q1 2026.

  • Quarterly Operating Leases rose 479.94% to $16.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.9 million through Mar 2026, up 479.94% year-over-year, with the annual reading at $17.5 million for FY2025, 406.86% up from the prior year.
  • Operating Leases hit $16.9 million in Q1 2026 for Summit Therapeutics, down from $17.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $17.5 million in Q4 2025 and bottomed at $1.3 million in Q2 2022.
  • Average Operating Leases over 5 years is $4.9 million, with a median of $3.3 million recorded in 2023.
  • The largest annual shift saw Operating Leases tumbled 51.47% in 2025 before it skyrocketed 479.94% in 2026.
  • Summit Therapeutics' Operating Leases stood at $2.8 million in 2022, then rose by 19.07% to $3.3 million in 2023, then grew by 4.95% to $3.5 million in 2024, then surged by 406.86% to $17.5 million in 2025, then decreased by 3.67% to $16.9 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Operating Leases are $16.9 million (Q1 2026), $17.5 million (Q4 2025), and $2.7 million (Q3 2025).